ASCO publishes a suite of peer-reviewed journals with content focused on
- clinical oncology research;
- issues and insights affecting oncology practice;
- cancer care, research, and care delivery issues unique to countries and settings with limited healthcare resources;
- biomedical informatics methods and processes applied to cancer-related data, information, and images; and
- the science and practice of precision oncology.
ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.
ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.
Publishing July 27, 2021, 4:00 pm ET:
Human Papilloma Virus Distribution Across the African Diaspora (Original Report)
Patricia Jeudin, et al.
Publishing July 26, 2021, 4:00 pm ET:
Acalabrutinib Versus Ibrutinib Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase 3 Trial (Original Report)
John Byrd, et al.
Second Generation Bruton’s Tyrosine Kinase Inhibitors: Simply the Best Treatments for CLL? (Editorial)
Deborah Stephens, et al.
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease (Original Report)
Michel Bolla, et al.
Payer Coverage of Integrative Medicine Interventions for Symptom Control in Patients With Cancer (Editorial)
Ramy Sedhom, et al.
When I Heard the Word Palliative”: Obscuring and Clarifying Factors Affecting the Stigma Around Palliative Care Referral in Oncology (Original Contribution)
Joanna Veazey Brooks, et al.
Publishing July 23, 2021, 4:00 pm ET:
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer (Original Report)
Jeremy Mason, et al.
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up (Original Report)
Jule Vasquez, et al.
Published July 22, 2021, 4:00 pm ET:
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women (Rapid Communication)
Fergus Couch, et al.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (Original Report)
Robin Kate Kelley, et al.
Impact of Pain on Employment and Financial Outcomes among Cancer Survivors (Original Report)
Michael Halpern, et al.
United States Trends in Opioid Access Among Patients with Poor Prognosis Cancer Near the End of Life (Original Report)
Andrea Enzinger, et al.
Changes in Burnout Among Oncology Physician Assistants Between 2015 and 2019 (Original Contribution)
Eric Tetzlaff, et al.
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia (Original Report)
Fisihatsion Tadesse, et al.
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer (Original Report)
Emmanuel Antonarakis, et al.
The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.